The rise of Viagra initially drove a surge for pharma, nevertheless recent shifts present a murky scenario for investors. Generic competitors are eating into earnings, and continued patent challenges add further https://dillanwvmm289222.blogs-service.com/72288143/the-blue-pill-and-the-pharmaceutical-industry-a-risky-play